Skip to Content


Active Substance: palifermin
Common Name: palifermin
ATC Code: V03AF08
Marketing Authorisation Holder: Swedish Orphan Biovitrum AB (publ)
Active Substance: palifermin
Status: Withdrawn
Authorisation Date: 2005-10-25
Therapeutic Area: Mucositis
Pharmacotherapeutic Group: All other therapeutic products

Therapeutic Indication

Kepivance is indicated to decrease the incidence, duration and severity of oral mucositis in adult patients with haematological malignancies receiving myeloablative radiochemotherapy associated with a high incidence of severe mucositis and requiring autologous-haematopoietic-stem-cell support.

The marketing authorisation for Kepivance has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.